Tenaya Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $82.16M
- P/E (TTM)
- –
- Dividend yield
- –
About Tenaya Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company that discovers and develops therapies targeting the underlying drivers of heart disease. Its lead product candidates include TN-201, an adeno-associated virus gene therapy in clinical trials for hypertrophic cardiomyopathy associated with MYBPC3 genetic variants, and TN-401, a gene therapy in clinical trials for arrhythmogenic right ventricular cardiomyopathy associated with PKP2 variants. The company also develops TN-301, a small molecule histone deacetylase 6 inhibitor investigated for heart failure with preserved ejection fraction and other disorders. Its target patient populations comprise individuals affected by rare genetic and prevalent cardiovascular conditions, and it collaborates with pharmaceutical partners.
The company conducts its activities in the United States, with facilities that include office and laboratory space in South San Francisco, California, as well as a manufacturing facility in Union City, California. Tenaya Therapeutics is headquartered in South San Francisco, California.
Summary of the business section of Tenaya Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Tenaya Therapeutics, Inc.
- Headquarters
- South San Francisco, CA
- Address
- 171 Oyster Point Blvd., Suite 500 94080
- Phone
- (415) 865-2066
- Website
- tenayatherapeutics.com
- Employees
- 70, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, San Francisco, California
Stock & identifiers
- Ticker
- TNYA
- Exchange
- Nasdaq
- IPO date
- Jul 30, 2021
- Shares outstanding
- 224M, Jul 30, 2026
- Public float
- $63.10M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1858848
- CUSIP
- 87990A106
- ISIN
- US87990A1060
- EIN
- 81-3789973
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Faraz Ali | Chief Executive Officer, Director | 539,782 |
| Whittemore Tingley | Chief Medical Officer | 263,073 |
| Eric J. Hyllengren | Chief Financial Officer | – |
| Tomohiro Higa | SVP, Finance | 118,267 |
| Chihiro Saito | SVP, Accounting and Fin. Ops. | 60,983 |
| Catherine Stehman-Breen | Director | 8,125 |
| June Lee | Director | – |
| Jeffrey T. Walsh | Director | – |
| Deepak Srivastava | Director | 564,101 |
| Amy L. Burroughs | Director | – |
| Karah Herdman Parschauer | Director | – |
| R. Sanders Williams | Director | 29,999 |
| David V. Goeddel | Director | 49,313,559 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 70 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 30, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Apr 18, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jul 30, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 23, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |